Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - immunotherapy
139
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
IgA Monoclonal Antibodies as a Prophylactic and Therapeutic Treatment for Dengue Virus Infection
Enables the prevention and treatment of dengue by avoiding the challenge of Antibody Dependent Enhancement. Background: Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths. In addition, dengue-associated illness comprises...
Published: 5/13/2025
|
Inventor(s):
Adam Waickman
,
Adam Wegman
,
Jeffrey Currier
,
Heather Friberg
,
Michael McCracken
,
Gregory Gromowski
Keywords(s):
antibody
,
antibody therapy
,
biologics
,
biomedical
,
disease prevention
,
immunotherapy
,
monoclonal antibody
,
Technologies
,
viral immunology
,
viral pathogenesis
Category(s):
Technology Classifications > Therapeutics and Vaccines
,
Technology Classifications > Antibodies
,
Technology Classifications > Healthcare
,
Technology Classifications > Viral Vectors
,
Campus > Upstate Medical University
A Method for treating TNF-α-driven pathologies via Fn14 inhibition
https://wsu.technologypublisher.com/files/sites/ncs_3618.pdf
Published: 4/30/2025
|
Inventor(s):
Salah-uddin Ahmed
,
Farheen Shaikh
Keywords(s):
anti-inflammatory
,
Immunotherapy
,
small molecule
,
Therapeutics
Category(s):
Technologies > Health & Well-being > Chemistry
Gene Modifications to Enhance the Function of PSC-Derived T Cells and NK Cells (UCLA Case No. 2023-129)
UCLA researchers in the Department of Medicine have generated novel pluripotent stem cell derived T cells that exhibit improved survival, expansion, and anti-tumor efficacy for use in cell therapy treatments. BACKGROUND: The Food and Drug Administration has approved several chimeric antigen receptor-T (CAR-T) cell therapies since 2017 to combat lymphoma...
Published: 4/22/2025
|
Inventor(s):
Christopher Seet
Keywords(s):
CAR-T cell therapy
,
Immunotherapy
,
pluripotent stem cell (PSC)
,
T-cell engineering
Category(s):
Therapeutics > Immunology And
Immunotherapy
,
Therapeutics > Gene Therapy And Editing
Reducing The Adverse Side Effects Of Using Native T-Cells To Destroy Cancer Cells
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected. Problem: Compounds which link native T-cells with the surface antigens found on cancer cells have emerged as an effective treatment for blood malignancies and are currently being developed for solid tumors....
Published: 4/16/2025
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
,
Protein/Peptide (Non-Antibody)
,
Small Molecule
Category(s):
Technology Classifications > Therapeutics
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025
|
Inventor(s):
Dennis Discher
,
Jason Andrechak
,
Lawrence Dooling
Keywords(s):
Antibody
,
Bioengineering
,
Cell Therapy
,
Drug Target
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA and CS1 for the Treatment of Multiple Myeloma (UCLA Case No. 2018-680)
UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND: Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American Cancer...
Published: 2/19/2025
|
Inventor(s):
Yvonne Chen
,
Eugenia Zah
Keywords(s):
Hematology
,
Immunotherapy
,
Life Science Research Tools
,
Therapeutics & Vaccines
Category(s):
Life Science Research Tools
,
Therapeutics > Immunology And
Immunotherapy
,
Therapeutics > Hematology
High-Throughput Approach to Identify New Lipid Nanoparticle Formulations for Vaccine and Drug Delivery
High-throughput in vivo screening method to identify lipid nanoparticle (LNP) formulations for local and systemic delivery for mRNA vaccines and cancer immunotherapies. Problem: Nucleic acid delivery is an attractive and rapidly growing area of research, particularly for the development of vaccines and cancer
immunotherapy
. Historically, viral vectors...
Published: 1/7/2025
|
Inventor(s):
Michael Mitchell
,
Alex Hamilton
Keywords(s):
Bioengineering
,
COVID-19
,
Drug Delivery
,
Gene Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Infectious Disease
,
Nanotechnology
Category(s):
Technology Classifications > Testing & Measurement
,
Technology Classifications > Vaccines
,
Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024
|
Inventor(s):
Ann Metzloff
,
Margaret Billingsley
,
Michael Mitchell
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Cell Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
3D Scaffold for T Cell Delivery and Suppression of Tregs for Solid Tumors (UCLA Case No. 2020-193)
SUMMARY: UCLA researchers in the Department of Bioengineering have developed a small and biodegradable implant that when placed adjacent to solid tumors, enhances immune response to cancer cells. BACKGROUND: The body’s immune system uses proteins called antibodies to train the immune response to foreign pathogens. This mechanism can combat...
Published: 2/14/2025
|
Inventor(s):
Manish Butte
Keywords(s):
cytokines
,
Drug Delivery
,
Immunotherapy
,
Nanoparticles
,
scaffolds
,
solid tumors
,
T-cell activation
,
t-cells
Category(s):
Platforms > Drug Delivery > Nanoparticles
1
2
3
4
5
6
7
8
9
10
...